Immune-related adverse events associated with mogamulizumab: a comprehensive review of the literature
Authors:
- 23 July 2024
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 24 (9) , 819-827
Abstract
Mogamulizumab is an anti-C-C chemokine receptor 4 antibody that is increasingly being used to treat T-cell malignancies such as cutaneous T-cell lymphoma, adult T-cell leukemia-lymphoma, and peripheral T-cell lymphoma. Because CCR4 is expressed on both malignant T-cells and regulatory T-cells (Tregs), mogamulizumab can be associated with increased immune-related adverse events (irAEs). While there is abundant literature on mogamulizumab-associated rash (MAR) and graft-versus-host disease (GVHD), other reported irAEs have not been collated into a single review. This narrative review covers irAEs associated with mogamulizumab in patients with T-cell lymphomas, focusing on events other than MAR and GVHD. We searched PubMed and Google Scholar for case reports, case series, chart reviews, and clinical trials published from inception to March 2024. Identified events include alopecia, vitiligo, arthritis, psoriasis, myocarditis, myositis/polymyositis, hepatitis, and others. Mogamulizumab's ability to augment the host immune response through Treg depletion adds to its efficacy but has wide-ranging implications for autoimmunity across multiple organ systems, similar to immune checkpoint inhibitor therapy. Occurrence of irAEs may be associated with improved overall clinical response, although long-term follow-up studies are needed.Keywords
This publication has 56 references indexed in Scilit:
- Multicenter, randomized, double-blind, placebo-controlled phase 3 study of mogamulizumab with open-label extension study in a minimum number of patients with human T-cell leukemia virus type-1-associated myelopathyJournal of Neurology, 2024
- EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2023European Journal of Cancer, 2023
- Clinical Characterization of Mogamulizumab-Associated Rash During Treatment of Mycosis Fungoides or Sézary SyndromeJAMA Dermatology, 2021
- The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Current and future approachesJournal of the American Academy of Dermatology, 2021
- Mogamulizumab-Associated Cutaneous Granulomatous Drug Eruption Mimicking Mycosis Fungoides but Possibly Indicating Durable Clinical ResponseJAMA Dermatology, 2019
- Long-term complete remission induced by mogamulizumab in a severe Sezary patient, together with five different possible auto-immune manifestationsEuropean Journal of Cancer, 2018
- Safety and efficacy of mogamulizumab in patients with adult T-cell leukemia–lymphoma in Japan: interim results of postmarketing all-case surveillanceInternational Journal of Hematology, 2017
- Multidisciplinary Management of Mycosis Fungoides/Sézary SyndromeCurrent Hematologic Malignancy Reports, 2017
- Colitis mimicking graft-versus-host disease during treatment with the anti-CCR4 monoclonal antibody, mogamulizumabInternational Journal of Hematology, 2015
- Sézary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC)Journal of the American Academy of Dermatology, 2010